Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy

<table>Freedom from biochemical progression (PSA <svg height="8.8500004" id="M22" style="vertical-align:-0.30096pt" version="1.1" viewbox="0 0 10.825 8.8500004" width="10.825" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,8.85)">
<g transform="translate(72,-64.92)">
<text transform="matrix(1,0,0,-1,-71.95,65.27)">
<tspan style="font-size: 12.50px; " x="0" y="0">&lt;</tspan>
</text>
</g>
</g>
</svg> 0.2 ng/mL, nadir +2) stratified per PSA elevation (<i>multivariate analysis</i>).</table>

Journal of Oncology

fig3

Figure 3

Figure 3: Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy 

Figure 3 | Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy 